JOANN And 3 Other Stocks Under $4 Insiders Are Aggressively Buying

The Dow Jones closed slightly lower on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Avalo Therapeutics

• The Trade: Avalo Therapeutics, Inc. AVTX 10% owner Caissa Capital Management Ltd acquired a total 25,000 shares an average price of $2.95. To acquire these shares, it cost around $73.87 thousand.
• What’s Happening: Avalo Therapeutics filed for mixed shelf of up to $375 million.
• What Avalo Therapeutics Does: Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases.

JOANN

• The Trade: JOANN Inc. JOAN EVP, CFO Scott Sekella acquired a total of 27,700 shares at an average price of $1.59. The insider spent around $44.04 thousand to buy those shares.
• What’s Happening: JOANN posted better-than-expected Q4 sales.
• What JOANN Does: JOANN Inc is engaged in the sewing business. The company provides fabrics, sewing supplies, yarn and needle arts, paper crafting, jewelry making, fabric crafting, craft lights, wedding decorations, and home decor products.

Check This Out: Check Out 3 High-Yielding Dividend Stocks In Real Estate Sector From Wall Street's Most Accurate Analysts

CNS Pharmaceuticals

• The Trade: CNS Pharmaceuticals, Inc. CNSP CFO Christopher Downs acquired a total of 3,100 shares at an average price of $3.20. To acquire these shares, it cost around $9.92 thousand.
• What’s Happening: CNS Pharmaceuticals announced it received approval from the Competent Authority and the central Ethics Committee in Italy for its potentially pivotal global trial evaluating Berubicin for the treatment of GBM..
• What CNS Pharmaceuticals Does: CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors.

Don’t forget to check out our premarket coverage here

MAIA Biotechnology

• The Trade: MAIA Biotechnology, Inc. MAIA Director Cristian Luput acquired a total of 1,576 shares at an average price of $3.69. The insider spent $5.82 thousand to buy those shares.
• What’s Happening: MAIA Biotechnology released topline data from the completed Part A safety lead-in of its THIO-101 Phase 2 go-to-market trial in advanced Non-Small Cell Lung Cancer (NSCLC) and has commenced recruitment in Part B randomized efficacy/dose selection.
• What MAIA Biotechnology Does: MAIA Biotechnology Inc is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer.